The estimated Net Worth of Andrew Frye is at least $1.92 Milion dollars as of 12 April 2021. Mr. Frye owns over 10,999 units of Baxter International stock worth over $355,040 and over the last 7 years he sold BAX stock worth over $1,566,343. In addition, he makes $0 as Senior Vice President and President i APAC at Baxter International.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Frye BAX stock SEC Form 4 insiders trading
Andrew has made over 3 trades of the Baxter International stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 10,999 units of BAX stock worth $932,605 on 12 April 2021.
The largest trade he's ever made was selling 10,999 units of Baxter International stock on 12 April 2021 worth over $932,605. On average, Andrew trades about 1,291 units every 39 days since 2017. As of 12 April 2021 he still owns at least 9,041 units of Baxter International stock.
You can see the complete history of Mr. Frye stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Frye biography
Andrew Frye is Senior Vice President and President, APAC of the Company. Mr. Frye joined Baxter in 2017 from DKSH Holdings Ltd., where he served as Global Head of Healthcare from 2015 to 2017. In that role, he oversaw a portfolio of pharmaceuticals, over-the-counter and device products across 13 countries. Previously, he served as Vice President of Business Development from 2011 to 2014 for DKSH Healthcare. Earlier in his career, he held a number of commercial roles with increasing responsibility at Abbott Laboratories’ Pharmaceutical and Nutrition divisions.
How old is Andrew Frye?
Andrew Frye is 54, he's been the Senior Vice President and President i APAC of Baxter International since 2017. There are 20 older and 8 younger executives at Baxter International. The oldest executive at Baxter International Inc. is James Gavin, 74, who is the Independent Director.
What's Andrew Frye's mailing address?
Andrew's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Insiders trading at Baxter International
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney oraz Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
What does Baxter International do?
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
What does Baxter International's logo look like?
Complete history of Mr. Frye stock trades at Baxter International
Baxter International executives and stock owners
Baxter International executives and other stock owners filed with the SEC include:
-
Jose Almeida,
Chairman of the Board, President, Chief Executive Officer -
James Saccaro,
Chief Financial Officer, Executive Vice President -
Jeanne Mason,
Senior Vice President - Human Resources -
Giuseppe Accogli,
Senior Vice President, President- America -
Sean Martin,
Senior Vice President, General Counsel -
Cristiano Franzi,
Senior Vice President and President, EMEA -
Jose E. Almeida,
Chairman, Pres & CEO -
Cristiano Franzi,
Sr. VP & Pres for EMEA -
Giuseppe Accogli,
Exec. VP & COO -
James K. Saccaro,
Exec. VP & CFO -
Sean B. W. Martin,
Sr. VP & Gen. Counsel -
Thomas Stallkamp,
Lead Independent Director -
Albert Stroucken,
Independent Director -
Peter Hellman,
Independent Director -
James Gavin,
Independent Director -
Patricia Morrison,
Independent Director -
Stephen Oesterle,
Independent Director -
Amy Wendell,
Independent Director -
John Forsyth,
Independent Director -
Michael Mahoney,
Independent Director -
Cathy Smith,
Independent Director -
Thomas Chen,
Independent Director -
Jacqueline Kunzler,
Senior Vice President and Chief Quality Officer -
Andrew Frye,
Senior Vice President and President, APAC -
Brian Stevens,
Senior Vice President, Chief Accounting Officer, Controller -
David S. Rosenbloom,
Sr. VP & Gen. Counsel -
Clare Trachtman,
VP of Investor Relations -
Brian C. Stevens,
Sr. VP, Chief Accounting Officer & Controller -
Wilber C. Boren IV,
Pres of Advanced Surgery -
Andrew Frye,
Sr. VP & Pres of APAC -
Jeanne K. Mason,
Sr. VP of HR -
Stacey Eisen,
Sr. VP of Global Communications -
Talvis P. Love,
Sr. VP & Chief Information Officer -
David P. Scharf,
Corporate Vice President -
Kees J Storm,
Director -
Marcus Schabacker,
CVP, Chief Scientific Officer -
Robert Felicelli,
CVP, Quality -
Brik V Eyre,
CVP, Hospital Products -
Carole J Uhrich,
Director -
Paul Vibert,
CVP, International -
Scott Pleau,
CVP - Operations -
Caroline Karp,
CVP, Controller -
Point Llc Loeb Daniel S Third,
-
Christopher A. Toth,
EVP,Group Pres, Kidney Care -
William A. Ii Ampofo,
Director -
Steven Flynn,
SVP, President, APAC -
Peter M Wilver,
Director -
David Brent Shafer,
Director -
Thomas J Jr Sabatino,
Senior Vice President -
Yuan Chia Pei,
Director -
Cheryl L White,
Corporate Vice President -
Joy A Amundson,
Corporate Vice President -
Jill M Schaaf,
CVP, Renal -
Harry M Jansen Jr Kraemer,
Chairman and -
Robert J. Hombach,
Corporate Vice President & CFO -
James E Utts,
Corporate Vice President -
Uma Chowdhry,
Director -
Peter J Arduini,
Corporate Vice President -
Bruce Mc Gillivray,
Corporate Vice President -
Sebastian J Bufalino,
Corporate Vice President -
Jean Luc Butel,
Corporate Vice President -
James M Gatling,
Corporate Vice President -
John C Moon,
Corporate Vice President -
Salto Carlos Del,
Senior Vice President -
Wayne T Hockmeyer,
Director -
Joseph B Martin,
Director -
Michael J Baughman,
Corporate Vice President -
Steven J Meyer,
Treasurer -
Michael J Tucker,
Senior Vice President -
James R Hurley,
Corporate Vice President -
Monroe E Trout,
Director -
Thomas Fang Tyan Chen,
Director -
Nevelle J Jeharajah,
Corporate Vice President -
Robert M Davis,
Corp. VP, CFO and Treasurer -
Jan Stern Reed,
Corporate Secretary -
Thomas H Glanzmann,
Senior Vice President -
Walter E Boomer,
Director -
Gail D Fosler,
Director -
Phillip L. Batchelor,
Corporate Vice President -
Karenann K Terrell,
Corporate Vice President -
Robert L Jr Parkinson,
Chairman of the Board and -
Karen J May,
Corporate Vice President -
Timothy P Lawrence,
CVP, Operations -
Blake E Devitt,
Director -
John J Greisch,
Senior Vice President & CFO -
Munib Islam,
Director -
Gregory P Young,
Corporate Vice President -
Susan R Lichtenstein,
Corporate Vice President, -
Lawrence T Gibbons,
Corporate Vice President -
David F Drohan,
Senior Vice President -
Fred L Turner,
Director -
Norbert G Riedel,
Corporate Vice President -
Brian P Anderson,
Senior Vice President -
Ludwig Hantson,
Corporate Vice President -
David S. Wilkes,
Director -
Nancy M Schlichting,
Director -
Joel T. Grade,
EVP and CFO -
Alok Sonig,
EVP,Group President, Pharma -
David S. Rosenbloom,
EVP and General Counsel -
Heather Knight,
EVP,Group Pres,Med Products -
Reazur Rasul,
EVP,Group Pres, Healthcare -
Jeffrey A Craig,
Director -
Stephen H Rusckowski,
Director -
James W Borzi,
EVP,Chief Supply Chain Officer